학술논문
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy
Document Type
article
Author
Source
Journal of Microbiology, Immunology and Infection, Vol 54, Iss 2, Pp 327-330 (2021)
Subject
Language
English
ISSN
1684-1182
Abstract
We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing.